Yang Hua, Zhao Qian, Chen Hai-Yan, Liu Wen, Ding Tong, Yang Bin, Song Jin-Chao
Department of Anesthesiology, Shidong Hospital of Shanghai, University of Shanghai for Science and Technology, Shanghai, China.
Department of Anesthesiology, Chongqing University Cancer Hospital, Chongqing, China.
Br J Clin Pharmacol. 2022 Mar;88(3):1279-1287. doi: 10.1111/bcp.15072. Epub 2021 Oct 8.
Propofol may result in hypotension, bradycardia and loss of protective reflexes, especially in elderly patients, while esketamine, a N-methyl-D-aspartate receptor antagonist, has analgesic, anaesthetic and sympathomimetic properties and is known to cause less cardiorespiratory depression. We hypothesized that esketamine may reduce the median effective concentration (EC ) of propofol and coadministration is less likely to produce hypotension during gastrointestinal endoscopy in elderly patients.
Ninety elderly patients, aged 65-89 years, undergoing gastrointestinal endoscopy were randomly assigned into 3 groups: SK0 (control) group (0 mg/kg esketamine); SK0.25 group (0.25 mg/kg esketamine); and SK0.5 group (0.5 mg/kg esketamine). Anaesthesia was achieved by plasma target-controlled infusion of propofol with different bolus doses of esketamine. The EC of propofol for gastrointestinal endoscopy was determined by using the up-and-down method of Dixon. The initial plasma target concentration is 2.5 μg/mL and the adjacent concentration gradient is 0.5 μg/mL. Cardiovascular variables were also measured.
Propofol EC s and its 95% confidence interval for gastrointestinal endoscopy in elderly patients were 3.69 (2.59-4.78), 2.45 (1.85-3.05) and 1.71 (1.15-2.27) μg/mL in the SK0, SK0.25 and SK0.5 groups, respectively (P < .05). The average percent change from baseline mean arterial pressure was -19.7 (7.55), -15.2 (7.14) and -10.1 (6.73), in the SK0, SK0.25 and SK0.5 groups, respectively (P < .001).
Combination medication of propofol with esketamine reduced the propofol EC during gastrointestinal endoscopy in elderly patients compared with administration of propofol without esketamine. Increasing doses of SK with propofol are less likely to produce hypotension with shorter recovery time.
丙泊酚可能导致低血压、心动过缓和保护性反射丧失,尤其是在老年患者中,而艾司氯胺酮作为一种N-甲基-D-天冬氨酸受体拮抗剂,具有镇痛、麻醉和拟交感神经特性,且已知其引起的心肺抑制较少。我们假设艾司氯胺酮可能降低丙泊酚的半数有效浓度(EC),并且在老年患者进行胃肠内镜检查期间联合用药不太可能产生低血压。
90例年龄在65 - 89岁接受胃肠内镜检查的老年患者被随机分为3组:SK0(对照组)(0mg/kg艾司氯胺酮);SK0.25组(0.25mg/kg艾司氯胺酮);和SK0.5组(0.5mg/kg艾司氯胺酮)。通过血浆靶控输注不同推注剂量艾司氯胺酮的丙泊酚来实现麻醉。采用Dixon上下法确定丙泊酚用于胃肠内镜检查的EC。初始血浆靶浓度为2.5μg/mL,相邻浓度梯度为0.5μg/mL。同时测量心血管变量。
SK0、SK0.25和SK0.5组中,老年患者胃肠内镜检查的丙泊酚EC及其95%置信区间分别为3.69(2.59 - 4.78)、2.45(1.85 - 3.05)和1.71(1.15 - 2.27)μg/mL(P <.05)。SK0、SK0.25和SK0.5组中,平均动脉压较基线的变化百分比分别为-19.7(7.55)、-15.2(7.14)和-10.1(6.73)(P <.001)。
与未使用艾司氯胺酮的丙泊酚给药相比,丙泊酚与艾司氯胺酮联合用药在老年患者胃肠内镜检查期间降低了丙泊酚的EC。丙泊酚联合增加剂量的艾司氯胺酮产生低血压的可能性较小,恢复时间较短。